Tetraphase Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:TTPH)
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) saw unusually large options trading activity on Thursday. Traders purchased 1,116 call options on the company. This is an increase of 1,792% compared to the average daily volume of 59 call options.
Several research analysts have recently issued reports on TTPH shares. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 28th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. BMO Capital Markets increased their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up $0.14 during mid-day trading on Monday, reaching $6.42. 315,005 shares of the company’s stock were exchanged, compared to its average volume of 500,242. The stock has a market capitalization of $330.08, a PE ratio of -2.24 and a beta of 2.51. Tetraphase Pharmaceuticals has a twelve month low of $3.57 and a twelve month high of $9.93.
In related news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the transaction, the insider now owns 8,750 shares in the company, valued at $52,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director L Patrick Gage purchased 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Canada Pension Plan Investment Board grew its stake in Tetraphase Pharmaceuticals by 54.4% during the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after acquiring an additional 900,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Tetraphase Pharmaceuticals by 32.7% during the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after purchasing an additional 360,552 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Tetraphase Pharmaceuticals during the third quarter valued at $7,915,000. Northern Trust Corp lifted its position in Tetraphase Pharmaceuticals by 4.8% during the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock valued at $6,323,000 after purchasing an additional 40,668 shares during the last quarter. Finally, Numeric Investors LLC lifted its position in Tetraphase Pharmaceuticals by 1,363.3% during the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares during the last quarter. 58.57% of the stock is owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.